Brean Capital analyst Jonathan Aschoff reiterated a Buy rating and boosted his price target on Regeneron Pharma (NASDAQ: REGN) to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Canaccord Genuity Raises PT of Regeneron Pharmaceuticals (REGN) to $525 from $460May 8, 2015 10:35 AM Regeneron Pharma (REGN) Estimates, PT Lifted at Piper JaffrayMay 8, 2015 7:39 AM Regeneron Pharma (REGN) PT Lifted to $490 at Roth CapitalMay 7, 2015 1:21 PM Regeneron (REGN) Tops Q1 EPS by 20c; Boosts U.S. EYLEA Sales OutlookMay 7, 2015 6:34 AM Regeneron Reports First Quarter 2015 Financial and Operating ResultsMay 7, 2015 6:30 AM